Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from Forbes referenced a study published in the November 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Persistence of Provider Directory Inaccuracies After the No Surprises Act,” found that provider directory inaccuracies lasted for longer than the expectation of 90 days that was mandated through federal regulation.
An article in the Marion County Record highlighted a news article published on AJMC.com, the website of AJMC. The article highlighted, “GoodRx, PBMs Hit by Price Fixing Lawsuits,” reported on class action lawsuits filed against both GoodRx and multiple pharmacy benefit managers due to the allegation that the companies conspired to fix prices to reduce reimbursements and increase fees for independent pharmacies.
Articles from Verify, TheStreet, and the Association of Health Care Journalists referenced an article published on AJMC.com. The article, “Trump Reverses Some Biden Drug Pricing Initiatives, Potentially Impacting Medicare Costs,” explained the effect of President Donald Trump’s executive order reversing Biden-era policies on both drug costs and aspects of the Affordable Care Act.
A writeup on AJMC.com, titled “Unlocking Early Colorectal Cancer Detection With Artificial Intelligence,” was referenced in an article by Inside Precision Medicine. The article covered the results of a study presented at the ASCO Gastrointestinal Cancers Symposium that found that an artificial intelligence model had 93.8% sensitivity and 19.7% specificity in detecting early colorectal cancer.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More